Harnessing MSK MRI for Clinical Trials
Weekday Course
ORGANIZERS: Alissa Burge, Hermien Kan, Jamie MacKay
Tuesday, 13 May 2025
320
15:45 -
17:45
Moderators: Chih-Liang Chin & Melissa Hooijmans
Skill Level: Intermediate
Session Number: Tu-03
No CME/CE Credit
Session Number: Tu-03
Overview
In this session, we will offer an overview of how MRI contributes to drug development, specifically in the musculoskeletal field. The event will commence with a broad look at imaging's role in clinical trials. Subsequently, two talks will delve into real-life applications of MRI in clinical trials for neuromuscular disease and arthritis. Finally, we will address the regulatory considerations surrounding the use of imaging endpoints.
Target Audience
Anyone with an interest in how MSK MRI (and MRI in general) can be used to enhance clinical trial design and delivery.
Educational Objectives
As a result of attending this course, participants should be able to:
• Recall the general roles that imaging can play in drug development;
• Explain specific applications of MSK MRI in clinical trials for neuromuscular disease and arthritis; and
• Describe the regulatory landscape governing the use of imaging endpoints in clinical trials.
| 15:45 | | Imaging in Drug Development 101 Thomas Fuerst |
| 16:15 | | MRI in Clinical Trials in Neuromuscular Disease Rebecca Willcocks |
| 16:45 | | MRI in Clinical Trials in Joint Disease John Waterton |
| 17:15 | | Regulatory Considerations for Use of Imaging Endpoints TBD |